The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Real-world outcomes of patients with BV and anti-PD-1 intolerant cHL: the impact of alloSCT & CAR-T
Timothy Voorhees, MD, MSCR, The Ohio State University Wexner Medical Center, Columbus, OH, shares the findings of a retrospective real-world analysis of data from 14 academic centers in the United States which investigated the long-term outcomes of patients with classical Hodgkin lymphoma (cHL) who were refractory or intolerant to brentuximab vedotin (BV) and anti-PD-1 therapy. Patients who received allogeneic stem cell transplantation (alloSCT) or CD30-directed CAR T-cell therapy had a longer overall survival (OS) than those not receiving these therapies. Dr Voorhees also reveals that rechallenging with BV or anti-PD-1 elicited a high overall response rate (ORR); however, median progression-free survival (PFS) was less than a year, and therefore, rechallenge may be considered as a bridging option in patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Novartis, Recordati; Research Funding: Recordati, AstraZeneca, Incyte, Morphosys.
